Value-Based Health Care in Inflammatory Bowel Disease.

Value-Based Health Care in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Nov 09;: Authors: Ahmed Z, Sarvepalli S, Garber A, Regueiro M, Rizk MK Abstract Inflammatory bowel disease (IBD) is a chronic inflammatory disease associated with significant resource utilization and health care burden. It is emerging as a global disease affecting an increasing proportion of the population. Along with evolving epidemiological trends, the paradigm of managing IBD has also changed. With a burgeoning repertoire of therapeutic options, improved use of health informatics, and emphasis on health care value, the treatment…

Read More

Erratum to Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threatening Complication.

Erratum to Ulcerative Colitis and Atypical Hemolytic-Uremic Syndrome: An Unusual But Potentially Life-threatening Complication. Inflamm Bowel Dis. 2018 Nov 08;: Authors: Viada Bris JF, Velasco Rodríguez-Belvís M, de Lucas Collantes C, Aparicio López C, Martínez de Azagra A, de Lama Caro-Patón G, de Prada Vicente I, Muñoz Codoceo RA PMID: 30407527 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30407527?dopt=Abstract

Read More

Epigenetics, DNA Organization, and Inflammatory Bowel Disease.

Epigenetics, DNA Organization, and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Nov 08;: Authors: Ray G, Longworth MS Abstract Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders affecting the gastrointestinal tract. The incidence of IBD is increasing, with more cases occurring in developed countries. Multiple factors such as genetics, environmental changes, gut microbiota, and immune abnormalities have been associated with development of IBD. In recent years, it has become increasingly apparent that epigenetic modifications of chromatin and the manner in which chromatin is organized in the nucleus are additionally important…

Read More

The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn’s Disease.

The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn’s Disease. Inflamm Bowel Dis. 2018 Nov 05;: Authors: Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R Abstract Background: Sleep disturbances (SDs) are commonly reported in patients with Crohn’s disease (CD). Several survey instruments assessing subjective measures of insufficient sleep have identified SDs in subjects with CD. However, there are limited data on objective measures of SDs in these patients as they relate to disease activity. In this prospective cross-sectional study, we compared objective estimates…

Read More

Authors’ reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn’s Disease Behavior, Fecal Calprotectin and Quality of Life.

Authors’ reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn’s Disease Behavior, Fecal Calprotectin and Quality of Life. Inflamm Bowel Dis. 2018 Oct 31;: Authors: Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM PMID: 30380064 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30380064?dopt=Abstract

Read More

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 Oct 25;: Authors: Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O’Byrne S Abstract Background: Sustaining clinical remission is an important treatment goal in moderate-to-severe UC. This post hoc exploratory analysis assessed the long-term efficacy of vedolizumab in the subset of patients with UC in the GEMINI 1 study who were in clinical remission by week 14 after 3…

Read More

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn’s and Colitis Foundation.

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn’s and Colitis Foundation. Inflamm Bowel Dis. 2018 Oct 24;: Authors: Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT Abstract There is significant interest among patients and providers in using cannabis (marijuana) and its derivatives to treat a number of chronic illnesses, including inflammatory bowel disease. Despite the Schedule I classification of cannabis by the federal government, state…

Read More

Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci.

Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci. Inflamm Bowel Dis. 2018 Oct 24;: Authors: Drobin K, Assadi G, Hong MG, Andersson E, Fredolini C, Forsström B, Reznichenko A, Akhter T, Ek WE, Bonfiglio F, Hansen MB, Sandberg K, Greco D, Repsilber D, Schwenk JM, D’Amato M, Halfvarson J Abstract Background: Few studies have investigated the blood proteome of inflammatory bowel disease (IBD). We characterized the serum abundance of proteins encoded at 163 known IBD risk loci and tested these proteins for their biomarker discovery…

Read More
<< Go Back